Zhengye Biotechnology Chairman's Letter to Shareholders Outlines Vision for 2026
Zhengye Biotechnology announced that Zhenfa Han, Chairman of the Board of Directors of Zhengye, has issued a letter to shareholders. "As we enter 2026, on behalf of the management of Zhengye Biotechnology Holding Limited, I am proud of the milestones we achieved in 2025 and would like to share our strategic vision for 2026 and the years ahead... Core Achievements in 2025: A Year of Strategic Execution and Innovation... Over the past year, we focused on strengthening our innovation capabilities, advancing regulatory milestones, and building operational excellence to capture opportunities in an evolving industry landscape. What guided us through these efforts was our unwavering commitment to becoming a world-leading manufacturer that delivers reliable veterinary vaccines to customers around the world. Every patent filed, every regulatory approval earned, and every capability enhanced represents a deliberate investment in our future competitiveness and our ability to better serve our customers... As we look to 2026, we are encouraged by the signs of gradual recovery of China's swine market, with industry expectations for a price inflection point around mid-year. More importantly, the capabilities we have built, our expanded product portfolio, strengthened international presence, and enhanced operational platforms provide a solid foundation for our next stage of growth. Building on our foundation, we plan to focus on the following strategic priorities: 1. Deepening Strategic Customer Engagement... 2. Strengthening Product Portfolio with Solution-Based Marketing... 3. Building an Empowering Customer Service Ecosystem... 4. Strategic Expansion into Companion Animal Sector... Together, we intend to continue to advance innovation and growth, and remain firmly committed to delivering sustainable, long-term value for our shareholders."
